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38-y-old East Asian woman pre-
sented in 1985 with weight gain and
cold intolerance. She was found to
have a small goiter and an elevated thyroid-
stimulating hormone (TSH) level of 58 mU/l
(normal range, 0.5–5). She was diagnosed
with primary hypothyroidism and was trea-
ted with levothyroxine (L-T4) 0.1 mg/d. Her
symptoms promptly improved. Between
1985 and 1993, she felt generally well. Her
adherence to treatment was variable, and
when she was reviewed her TSH levels were
raised on several occasions (in the range of
15–38 mU/l). In her past medical history, she
had an ectopic pregnancy in 1990 and
bilateral oophorectomy in 2000 for benign
cystadenomas. There was no family history of
thyroid or autoimmune diseases.
While the patient was on vacation in the
summer of 1993, she stopped taking L-T4
altogether. Upon her return, thyroid function
tests (TFTs) showed a TSH level of 0.46 mU/l,
free thyroxine (FT4) at 15 pmol/l (normal
range, 11–24), and thyroid hormone T3 at 1.9
nmol/l (normal range, 1.0–2.5). Antimicroso-
mal antibody titer was 1:400. Between June
1994 and November 1998, she continued to
feel well on no treatment. TSH was measured
annually and remained normal (range, 0.8–
1.6 mU/l).
On 3 June 1999, the patient presented
with palpitations, heat intolerance, excessive
sweating, and anxiety. She also reported eye
staring but no diplopia, proptosis (bulging
eyes), or eye pain. She had no neck pain,
dysphagia, or change in voice. She was
clinically thyrotoxic with tachycardia, tremor,
lid lag, and retraction. She had a symmetrical
goiter, 40 g in size, that was firm, non-tender,
and mobile with no distinct nodules or bruits.
Hertel exophthalmometric measurements
were 18 mm in both eyes (normal is up to
18 mm). The rest of the examination was
unremarkable. TSH was less than 0.06 mU/l
and FT4 was 31 pmol/l (Figure 1). Liver
enzymes were normal. Radioiodine uptake
was 41% (normal range, 25%–35%) at 24 h
with homogeneous distribution of the tracer.
On 8 June 1999, the patient was started on
methimazole 20 mg/d. By 2 July 1999, she
was feeling well, and TFTs showed FT4 at 24
pmol/l, T3 at 2.2 nmol/l, and TSH at less than
0.06 mU/l. On 25 July 1999, she was treated
with 14 mCi of I
131. On 2 September 1999,
the patient presented with severe symptoms
of palpitations, heat intolerance, tremor,
headache, nausea, and vomiting. Clinically,
she was severely thyrotoxic, with a regular
pulse of 110/min, and an oral temperature of
37.4 8C. She was irritable but fully conscious
and oriented. She had lid lag and retraction
and mild proptosis of the left eye (20 mm).
The goiter was the same size (40 g) and
consistency as during her presentation on 3
June1999, but it was now moderately tender.
TFTs showed FT4 at more than 77 pmol/l, T3
at 6.4 nmol/l, and TSH at less than 0.06 mU/l.
Methimazole was increased to 15 mg three
times a day. Because of the severity of her
hyperthyroidism, Lugol’s solution was added
at five drops, three times a day, for 14 d. The
patient declined corticosteroids.
After a few days, she felt better and repeat
FT4 was 42 pmol/l and TSH was less than 0.06
mU/l. Liver enzymes, however, were now
raised: AST at 95 U/l, ALP at 372 U/l, and total
bilirubin at 10 lmol/l. The methimazole was
discontinued and replaced 2 wk later with
propylthiouracil at a dose of 100 mg twice
daily. The patient continued to improve over
the following several weeks. Liver enzymes
slowly normalized after about 2.5 mo. On 3
November 1999, the propylthiouracil was
discontinued. TFTs done 2 and 4 wk later
showed FT4 at 6 and 5 pmol/l and TSH at 18
and 30 mU/l, respectively. It was thought that
this might be a transient hypothyroidism
after I
131 therapy or a permanent post-
ablation hypothyroidism. The latter was
considered more likely, and therefore the
patient was started on L-T4. Five weeks later,
she was doing well, and was clinically
euthyroid with FT4 of 16 pmol/l and TSH of
0.8 mU/l.
PLoS Medicine | www.plosmedicine.org May 2005 | Volume 2 | Issue 5 | e89 0401
Open access, freely available online PLoS MEDICINEIn February 2000, the patient presented with symptoms of
hyperthyroidism and her TSH was low, at 0.05 mU/l. L-T4 was
discontinued, but she remained hyperthyroid 2 mo later. She
was then started on methimazole 10 mg once daily. In May
2000, a repeat 24-h radioiodine uptake was elevated at 65%.
The patient was continued on methimazole until December
2000, when the drug was discontinued because the patient
was found to be euthyroid.
She remained euthyroid off all treatment for 2 mo, but in
March 2001, she started to have symptoms of hypothyroid-
ism and her TSH rose to 22 mU/l, with a FT4 of 9.2 pmol/l.
She was started on L-T4 50 lg once daily, on which she
remained euthyroid with repeatedly normal TFTs. Between
March 2001 and December 2004, she remained euthyroid on
L-T4 50 lg once daily (TSH ranged between 1.2 and 2.8 mU/
l). She was last seen on 11 December 2004, when she was
clinically and biochemically euthyroid with FT4 of 18.4 pmol/l
and TSH of 2.8 mU/l.
DISCUSSION
The two main disorders that comprise autoimmune thyroid
disease are Hashimoto thyroiditis and Graves disease. The
former is the most common cause of hypothyroidism,
whereas the latter is a major cause of hyperthyroidism.
Occasionally, a patient may present with features of one of
these disorders at one time and features of the other at
another time. The usual sequence is hyperthyroidism
followed by hypothyroidism [1]. However, cases of hypo-
thyroidism followed by hyperthyroidism, such as in our
patient, have also been described [2]. Our patient developed
Graves disease after many years of hypothyroidism followed
by a similar period of euthyroidism. The initial phase of
hypothyroidism was secondary to Hashimoto thyroiditis since
the patient had goiter and high antimicrosomal antibodies.
The hypothyroidism did not represent a hypothyroid phase
of an episode of thyroiditis since the patient repeatedly had
elevated TSH levels over several years when she was not
adhering to L-T4 therapy. Interestingly, following treatment
with I
131, she developed multiple alternating phases of
hypothyroidism and hyperthyroidism (Figure 1). It is possible
that the thyroiditis caused by I
131 induced some immune
reaction, with the formation of stimulating and inhibiting
antibodies leading later to alternating phases of hypo- and
hyperthyroidism.
Takasu et al. described eight cases of autoimmune thyroid
disease with an alternating pattern of thyroid function [2]. In
ﬁve cases, hypothyroidism was followed by transient hyper-
thyroidism. In two other cases, hypothyroidism was followed
by persistent hyperthyroidism, and in one case hypothyroid-
ism was associated with thyroid-stimulating antibodies, a
characteristic ﬁnding in Graves disease. Tamai et al. reported
the development of spontaneous hypothyroidism in 26
patients with Graves disease treated with antithyroidal drugs
[1]. In another reported case, a patient underwent three
cycles of transition from hypo- to hyperthyroidism and back
to hypothyroidism, with corresponding changes in stimulat-
ing and blocking TSH receptor antibodies [3]. In our patient,
we did not have serial measurements of stimulating and
blocking thyroid antibodies. However, it is likely that the
alternating thyroid function was associated with an alternat-
ing pattern of antibodies.
Recovery from hypothyroidism in chronic autoimmune
thyroiditis is a rare but recognized phenomenon [4]. This is
more likely to happen after iodide restriction in countries
with high dietary iodide intake [5]. Predictors of spontaneous
recovery from hypothyroidism in Hashimoto thyroiditis
include the presence of goiter and high radioiodine uptake
[5–7]. Spontaneous recovery also has been related to the
disappearance of TSH-receptor-blocking antibodies [8].
Our patient had severe hyperthyroidism 5 wk after I
131
treatment, while she was taking a relatively large dose of
methimazole. This was most likely secondary to I
131-induced
thyroiditis as there was tenderness of the thyroid gland and
FT4 increased proportionally much more than T3. The use of
thionamide drugs to establish euthyroidism prior to I
131
treatment is controversial, especially in a young patient
without cardiovascular disease [9,10]. While rare, severe
hyperthyroidism and even thyroid storm have been described
following I
131 treatment of Graves disease [11].
The patient also developed elevated liver enzymes. This
could be secondary to the severe hyperthyroidism per se or
due to the high dose of methimazole. Elevated liver enzymes
are occasionally seen as a manifestation of hyperthyroidism
and are also a well-recognized complication of antithyroid
drugs [12–14].
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Figure 1. Alternating Thyroid Function over Time
Numbered time points: (1) initial diagnosis of hypothyroidism; (2) off
L-T4 for 5 wk while on vacation; (3) presentation with Graves’ disease;
(4) I
131 treatment; (5) severe hyperthyroidism 5 wk after I
131
treatment; (6) a few days after treatment with propylthiouracil,
propranalol, and Lugol’s solution; (7) hypothyroidism about 4 mo
after I
131 treatment off all medications; (8) hypothyroidism conﬁrmed
with another set of TFTs and L-T4 started; (9) relapse of hyper-
thyroidism and L-T4 discontinued; (10) hyperthyroidism conﬁrmed
and methimazole started; (11) hypothyroidism developed and L-T4
resumed.
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Learning Points
 Rarely, autoimmune hyperthyroidism can occur after many
years of hypothyroidism in patients with Hashimoto thyroiditis.
 When a patient on L-T4 for Hashimoto hypothyroidism
presents with hyperthyroidism, over-replacement with L-T4 is
the likely cause, but the possibility of endogenous hyper-
thyroidism should also be considered.
 Although radioactive iodine therapy for Graves disease is
generally safe, especially in an otherwise healthy patient, severe
exacerbations of hyperthyroidism can occur, and close monitor-
ing in the first few weeks after therapy is prudent.
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